Serum Institute of India conducts phase III trial of BCG vaccine for COVID-19
The DBT statement quoting Adar Poonawalla, the owner and CEO of Serum Institute of India(SII) said,"We are delighted to partner with DBT-BIRAC for this study and look forward to the positive results of the trial, which should be available before the end of this year."
Advertisement
New Delhi: The Serum Institute of India is conducting phase III clinical trial of BCG vaccine candidate VPM1002 to evaluate its ability in reducing infection and severe disease outcomes of COVID-19 among high-risk persons of advanced age, comorbidities and high-exposure healthcare workers (HCWs), the Department of Biotechnology said in a statement.
About 6,000 health workers and high-risk individuals including those in close contact of COVID-19 patients have been enrolled in a clinical trial to determine if the recombinant Bacillus Calmette-Guerian (rBCG) can boost immunity to fight against the virus, the statement added.
The BCG vaccine is administered routinely to all newborns as part of the national childhood immunisation programme to prevent tuberculosis (TB), an infection caused by bacteria that mainly affects the lungs.
It has beneficial heterologous effects and proven antiviral and immune modulatory properties that protect against infectious diseases through the induction of trained innate immunity and heterologous adaptive immunity.
"Serum Institute of India Pvt Ltd (SIIPL) has been supported under Department of Biotechnology's National Biopharma Mission for the conduct of a multi-site randomised double-blinded placebo-controlled phase III clinical trial of a recombinant BCG vaccine candidate, VPM1002.
"The objective of this trial is to evaluate the ability of VPM1002 in reducing infection incidence and severe disease outcomes of COVID-19 among high-risk persons of advanced age or co-morbidities and high-exposure healthcare workers (HCWs)," the statement said.
Renu Swarup, Secretary, DBT and Chairperson, BIRAC said the BCG vaccine is a proven platform and utilising its off-target effects for diseases other than TB is a very pragmatic approach to take.
"The trial began in May 2020 and has completed enrolment of 6,000 subjects in almost 40 hospitals across the country. This is an important milestone in the quest for preventing the disease and we look forward to the results of this important trial," she said.
The DBT statement quoting Adar Poonawalla, the owner and CEO of Serum Institute of India (SII) said, "We are delighted to partner with DBT-BIRAC for this study and look forward to the positive results of the trial, which should be available before the end of this year."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.